A sponsor-CRO governance model is the operating architecture that defines how decisions are made, how accountability is distributed, and how issues are escalated between a sponsor and its contracted CRO across the life of a clinical trial. Most sponsors have one. Most are designed with care and with genuine intent. What is interesting, and worth examining closely, is that governance failure in clinical development almost never happens because the architecture was wrong. It happens because the accountability and communication behaviours that the architecture depends on were assumed rather than built, and the first real pressure scenario exposed both gaps simultaneously. The strategy was sound. The execution layer beneath it was not.
What Governance Is Actually Supposed to Do
There is a version of governance that exists primarily as a compliance artefact: the org chart, the RACI matrix, the meeting cadence, the escalation log. These documents may satisfy an audit. They do not by themselves govern anything.
Governance, in the context of a clinical development program, serves a specific function. It provides the structure through which the sponsor retains decision authority over a complex, distributed set of operations being carried out, in whole or in part, by external vendors. It creates the conditions under which accountability can be exercised rather than assumed. And it establishes the communication infrastructure that allows the sponsor to remain genuinely informed rather than formally updated.
What stands out across governance models that function well under pressure is not their complexity but their specificity. They are precise about who decides, not just who is involved. They are honest about what the sponsor team can realistically monitor, rather than aspirational about what they intend to. And they are designed to hold under conditions that are worse than the ones assumed when they were built.
The Strategy-Execution Gap: Where Governance Models Lose Their Way
Governance models are typically designed at a moment of relative calm and with access to time and careful thinking that will not be available once trial execution is underway. The assumptions embedded in the design, often without awareness, reflect that calm rather than the conditions that will test it.
Consider a common scenario. A governance structure is designed that includes a joint steering committee meeting quarterly, a project management meeting monthly, and an escalation path that routes issues through defined roles to a senior sponsor decision-maker. Each element looks right. Each element was discussed and agreed. And then execution begins.
The joint steering committee meeting in month three is postponed because two key stakeholders have conflicting priorities. The project management meeting becomes a status report exchange because neither party is raising difficult questions. An issue surfaces in month four that needs a decision, and it is not immediately clear whether it routes to the sponsor project lead or the steering committee, because the escalation criteria were defined at a level of generality that does not map cleanly onto the specific situation at hand.
This is not a governance model that was badly designed. It is a governance model that was designed for ideal conditions and has now encountered real ones.
Accountability Architecture: Who Owns What and Who Verifies It
The most consistent gap in governance models that fail under execution pressure is not documentation. It is the absence of a clear and actively maintained answer to two questions: who retains the authority to decide when something goes wrong, and who is responsible for verifying that the governance system is functioning as designed?
| Governance Component | Most Common Gap | Consequence Under Pressure |
|---|---|---|
| Decision rights | Defined at senior level; ambiguous at operational level | Operational teams escalate everything; decisions slow; timeline slips while authority is established |
| Accountability retention | Implied in the contract; not actively maintained by the sponsor | Ownership diffuses at the first point of conflict; resolution stalls |
| Communication protocol | Cadence set; what actually gets said is untested | Meetings become status reports; real problems are not raised |
| Escalation path | Documented; never practiced against a realistic scenario | Issues surface at the wrong level; resolution is delayed |
Drawing on 13 years of experience and work across more than 40 clinical development programs, Sabine Hutchison, Co-Founder and Co-CEO at Seuss+, has observed a consistent pattern across governance engagements: the component most frequently absent when a sponsor-CRO relationship escalates is not the governance structure itself. It is a clear and shared understanding of who retains decision authority when that structure comes under pressure.
The distinction between having a governance structure and having a governance architecture that functions under pressure is not subtle. It is the difference between a trial that can absorb an unexpected scope change and one that cannot.
Communication Discipline in Governance: How to Test Alignment Before You Need It
Governance documents can establish communication cadence. They cannot establish whether the communication that happens within that cadence is honest, complete, and useful. That requires something different, and it requires it before the governance structure is tested by a real scenario.
What Sabine Hutchison, Co-Founder and Co-CEO at Seuss+, describes as communication discipline in governance is the practice of testing alignment actively rather than assuming it from the existence of a meeting cadence or a shared reporting template. This means asking questions at governance checkpoints that a polished status report cannot answer: what is the single biggest risk to the next milestone that we have not yet addressed? What decision would we make differently if we had more information today? Is there anything the team is concerned about that has not been raised formally yet?
These are not complicated questions. They are questions that require a governance relationship with enough trust and safety in it for honest answers to be possible. Creating that relationship is a leadership responsibility, not a governance process output.
The Vendor Relationship Maximization Method (VRMM), the system developed by Seuss+ and applied across clinical development programs, structures Infrastructure Setup, its third stage, around exactly this principle: governance infrastructure is built for real conditions, including communication protocols that are tested rather than assumed and KPI frameworks that surface genuine performance signals rather than demonstrating compliance with a reporting cadence.
What Functional Governance Looks Like Under Pressure
A governance model that functions under pressure has a specific set of characteristics that distinguish it from one that functions on paper.
Escalations resolve at the correct level because decision rights are understood operationally, not just structurally. Scope changes are assessed against both the contract and the program strategy before they are agreed, because the sponsor maintains enough programme awareness to evaluate the implications. Problems surface early because the communication dynamic in the governance relationship makes honesty viable rather than costly.
What is worth acknowledging here is that this is harder for pre-commercial biotechs with lean internal teams than it is for larger, more resourced sponsors. The bandwidth required for substantive governance is real, and it competes with every other priority a small team is managing. This does not change what effective governance requires. It does change how it needs to be designed: proportionate to what the team can genuinely sustain, structured enough to hold when it is most needed, and supported by an operational partner who can maintain the governance architecture alongside the sponsor rather than as a separate activity.
Governance that looks right is not the same as governance that works. The gap between those two states is where most clinical development programs encounter problems that were preventable.
Key Industry Data
- Tufts Center for the Study of Drug Development: Research from Tufts CSDD has consistently documented that sponsor-CRO relationship and governance failures rank among the leading organisational contributors to clinical trial delays, with relationship management and oversight gaps accounting for a disproportionate share of avoidable cost increases across Phase 2 and Phase 3 programs.
- ICH E6(R2), Risk-Based Approach to Monitoring: The 2016 revision of ICH E6 formally introduced risk-based oversight principles, reinforcing that governance structures must be proportionate to program complexity and must include mechanisms for the sponsor to identify and address issues, not merely receive reports about them.
- EMA Reflection Paper on Risk-Based Quality Management: The EMA has noted that governance failures in clinical programs frequently stem from sponsors relying on CRO reporting as their primary oversight mechanism, rather than maintaining the independent oversight capability that regulatory frameworks require.
- FDA Guidance for Industry: Oversight of Clinical Investigations, A Risk-Based Approach to Monitoring (2013): This FDA guidance document reinforces sponsor responsibility for monitoring design and execution, noting that the complexity of delegated arrangements increases, rather than decreases, the sponsor’s oversight obligations.
- TransCelerate Shared Investigator Platform and Vendor Oversight Research: TransCelerate BioPharma’s collaborative research on vendor oversight standardisation has identified decision right ambiguity and communication protocol gaps as the two most commonly cited root causes in post-trial governance reviews conducted across member companies.
Questions this perspective tends to raise
What should a sponsor-CRO governance model include?+
A functional sponsor-CRO governance model should include clearly defined decision rights at both the strategic and operational level; documented escalation paths that are known to and practiced by all parties; substantive KPIs that reflect meaningful delivery signals rather than activity counts; a communication protocol that has been tested rather than assumed; and a change control process that connects scope decisions to accountability at the sponsor level. The architecture needs to function under real trial conditions, not just under the conditions assumed during design.
Why do governance models that look good on paper fail during trial execution?+
Governance models typically fail at execution because they are designed for ideal conditions rather than the conditions that arise during a clinical trial. Two underlying gaps drive most failures: accountability that was implied at the sponsor level rather than actively retained, and communication alignment that was declared at kick-off rather than tested before it was needed. When the first unplanned scenario occurs, these gaps surface as stalled escalations, ambiguous decision authority, and communication breakdowns that no one anticipated.
How do you test whether your governance model is actually working?+
Testing governance effectiveness involves running the model against realistic pressure scenarios before they occur naturally. Ask who makes a specific escalation decision and verify all parties agree. Check whether teams at the operational level know where authority sits without consulting a governance document. Review whether governance meetings produce decisions or only status updates. Ask CRO counterparts whether they would raise an early concern immediately or wait for certainty. Where answers are inconsistent or uncertain, the governance structure has gaps that will surface under pressure.
What is the difference between governance structure and governance behaviour?+
Governance structure is the documented architecture: the org chart, the escalation matrix, the meeting cadence, the KPI dashboard. Governance behaviour is how that architecture is used in practice when the pressure is real. A well-designed governance structure will not prevent failure if the behaviours that activate it are absent. This includes the sponsor team asking substantive questions rather than accepting polished status reports, the CRO raising concerns early rather than waiting until they are visible, and decision-makers treating governance checkpoints as accountability moments rather than compliance events.
How does poor governance contribute to clinical trial delays and budget overruns?+
Poor governance contributes to delays and overruns through several compounding mechanisms. Unresolved escalations stall decisions with timeline consequences. Ambiguous accountability leads to problems persisting longer than necessary because no one is certain who owns the resolution. Communication gaps allow misalignments to compound invisibly until they surface as scope disputes or delivery failures. Inadequate change control allows scope expansion without corresponding budget and timeline adjustment. Each of these mechanisms is individually costly; in combination, they represent the majority of avoidable program cost increases in clinical development. —
In context
This argument sits inside an industry where the cost of every clinical program is rising and the margin for recovering from a governance error is narrowing. The two numbers below are the shape of that pressure.
Execution is not strategy. The governance model is the operating architecture that decides whether strategy reaches patients.
